{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:40:56Z","timestamp":1790991656549,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>IL-23 and IL-27 are believed to be involved in the pathogenesis of Guillain-Barr\u00e9 syndrome (GBS). However, changes in these cytokines during the dynamic pathological and recovery processes of GBS are not well described. In the present study, plasma was collected from 83 patients with various stages of GBS, 70 patients with central nervous system demyelinating diseases,70 patients with other neurological diseases (OND) and 70 age- and sex-matched healthy volunteers. Serum levels of IL-23, IL-27, and <jats:italic>Campylobacter jejuni<\/jats:italic> (CJ) IgM were assessed using enzyme linked immunosorbent assay (ELISA). We found that serum IL-23 levels of patients during the acute phase of GBS were significantly higher followed by a decreasing trend during the recovery phase of the disease. Serum IL-27 levels significantly increased during the acute phase of GBS, and gradually increased during the recovery phase. Interestingly, both the severity and subtype of GBS were closely associated with the two cytokines. IL-23 levels were positively correlated with IL-27 levels, prognosis, and other clinical parameters. Our findings confirm that IL-23 may show pro-inflammatory effects, especially at the early stage of GBS. IL-27 appears to have a dual role in GBS, with initial pro-inflammatory effects, followed by anti-inflammatory properties during recovery.<\/jats:p>","DOI":"10.1038\/s41598-018-21025-5","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T11:43:00Z","timestamp":1517917380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["IL-23 and IL-27 Levels in Serum are Associated with the Process and the Recovery of Guillain-Barr\u00e9 Syndrome"],"prefix":"10.1038","volume":"8","author":[{"given":"Jing","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifei","family":"Shou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanfeng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"key":"21025_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.pop.2015.01.001","volume":"42","author":"V Ansar","year":"2015","unstructured":"Ansar, V. & Valadi, N. Guillain-Barr\u00e9 syndrome. Prim Care 42, 189\u2013193, https:\/\/doi.org\/10.1016\/j.pop.2015.01.001 (2015).","journal-title":"Prim Care"},{"key":"21025_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/B978-0-444-52902-2.00021-7","volume":"115","author":"H Fujimura","year":"2013","unstructured":"Fujimura, H. The Guillain-Barr\u00e9 syndrome. Handb Clin Neurol 115, 383\u2013402, https:\/\/doi.org\/10.1016\/B978-0-444-52902-2.00021-7 (2013).","journal-title":"Handb Clin Neurol"},{"key":"21025_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.mayocp.2016.12.002","volume":"92","author":"EF Wijdicks","year":"2017","unstructured":"Wijdicks, E. F. & Klein, C. J. Guillain-Barr\u00e9 Syndrome. Mayo Clin Proc 92, 467\u2013479, https:\/\/doi.org\/10.1016\/j.mayocp.2016.12.002 (2017).","journal-title":"Mayo Clin Proc"},{"key":"21025_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrneurol.2016.172","volume":"12","author":"JA Goodfellow","year":"2016","unstructured":"Goodfellow, J. A. & Willison, H. J. Guillain-Barr\u00e9 syndrome: a century of progress. Nat Rev Neurol 12, 723\u2013731, https:\/\/doi.org\/10.1038\/nrneurol.2016.172 (2016).","journal-title":"Nat Rev Neurol"},{"key":"21025_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2183\/pjab.88.299","volume":"88","author":"N Yuki","year":"2012","unstructured":"Yuki, N. Guillain-Barr\u00e9 syndrome and anti-ganglioside antibodies: a clinician-scientist\u2019s journey. Proc Jpn Acad Ser B Phys Biol Sci 88, 299\u2013326 (2012).","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"21025_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jnnp.2010.226639","volume":"82","author":"J Drenthen","year":"2011","unstructured":"Drenthen, J. et al. Guillain-Barr\u00e9 syndrome subtypes related to Campylobacter infection. J Neurol Neurosurg Psychiatry 82, 300\u2013305, https:\/\/doi.org\/10.1136\/jnnp.2010.226639 (2011).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"21025_CR7","doi-asserted-by":"publisher","first-page":"852195","DOI":"10.1155\/2013\/852195","volume":"2013","author":"KK Nyati","year":"2013","unstructured":"Nyati, K. K. & Nyati, R. Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barr\u00e9 syndrome: an update. Biomed Res Int 2013, 852195, https:\/\/doi.org\/10.1155\/2013\/852195 (2013).","journal-title":"Biomed Res Int"},{"key":"21025_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/1531-8249(200010)48:4<624::AID-ANA9>3.0.CO;2-O","volume":"48","author":"K Ogawara","year":"2000","unstructured":"Ogawara, K. et al. Axonal Guillain-Barr\u00e9 syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48, 624\u2013631 (2000).","journal-title":"Ann Neurol"},{"key":"21025_CR9","doi-asserted-by":"publisher","unstructured":"Russo, F. B., Jungmann, P. & Beltrao-Braga, P. C. B. Zika infection and the development of neurological defects. Cell Microbiol 19, https:\/\/doi.org\/10.1111\/cmi.12744 (2017).","DOI":"10.1111\/cmi.12744"},{"key":"21025_CR10","doi-asserted-by":"publisher","first-page":"758639","DOI":"10.1155\/2014\/758639","volume":"2014","author":"KK Nyati","year":"2014","unstructured":"Nyati, K. K. & Prasad, K. N. Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barr\u00e9 syndrome. Mediators Inflamm 2014, 758639, https:\/\/doi.org\/10.1155\/2014\/758639 (2014).","journal-title":"Mediators Inflamm"},{"key":"21025_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/14728222.2017.1258402","volume":"21","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. Tumor necrosis factor-alpha in Guillain-Barr\u00e9 syndrome, friend or foe? Expert Opin Ther Targets 21, 103\u2013112, https:\/\/doi.org\/10.1080\/14728222.2017.1258402 (2017).","journal-title":"Expert Opin Ther Targets"},{"key":"21025_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.it.2005.10.003","volume":"27","author":"BS McKenzie","year":"2006","unstructured":"McKenzie, B. S., Kastelein, R. A. & Cua, D. J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 27, 17\u201323, https:\/\/doi.org\/10.1016\/j.it.2005.10.003 (2006).","journal-title":"Trends Immunol"},{"key":"21025_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jmb.2008.07.051","volume":"382","author":"PJ Lupardus","year":"2008","unstructured":"Lupardus, P. J. & Garcia, K. C. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. J Mol Biol 382, 931\u2013941, https:\/\/doi.org\/10.1016\/j.jmb.2008.07.051 (2008).","journal-title":"J Mol Biol"},{"key":"21025_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","volume":"135","author":"C Tang","year":"2012","unstructured":"Tang, C., Chen, S., Qian, H. & Huang, W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 135, 112\u2013124, https:\/\/doi.org\/10.1111\/j.1365-2567.2011.03522.x (2012).","journal-title":"Immunology"},{"key":"21025_CR15","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/archneur.63.6.858","volume":"63","author":"W Hu","year":"2006","unstructured":"Hu, W., Dehmel, T., Pirhonen, J., Hartung, H. P. & Kieseier, B. C. Interleukin 23 in acute inflammatory demyelination of the peripheral nerve. Arch Neurol 63, 858\u2013864, https:\/\/doi.org\/10.1001\/archneur.63.6.858 (2006).","journal-title":"Arch Neurol"},{"key":"21025_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cyto.2015.01.030","volume":"75","author":"L Sun","year":"2015","unstructured":"Sun, L., He, C., Nair, L., Yeung, J. & Egwuagu, C. E. Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease. Cytokine 75, 249\u2013255, https:\/\/doi.org\/10.1016\/j.cyto.2015.01.030 (2015).","journal-title":"Cytokine"},{"key":"21025_CR17","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1189\/jlb.0609445","volume":"86","author":"H Yoshida","year":"2009","unstructured":"Yoshida, H., Nakaya, M. & Miyazaki, Y. Interleukin 27: a double-edged sword for offense and defense. J Leukoc Biol 86, 1295\u20131303, https:\/\/doi.org\/10.1189\/jlb.0609445 (2009).","journal-title":"J Leukoc Biol"},{"key":"21025_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/ni1375","volume":"7","author":"M Batten","year":"2006","unstructured":"Batten, M. et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 7, 929\u2013936, https:\/\/doi.org\/10.1038\/ni1375 (2006).","journal-title":"Nat Immunol"},{"key":"21025_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0919-1","volume":"14","author":"PH Lalive","year":"2017","unstructured":"Lalive, P. H. et al. Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients. J Neuroinflammation 14, 144, https:\/\/doi.org\/10.1186\/s12974-017-0919-1 (2017).","journal-title":"J Neuroinflammation"},{"key":"21025_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cca.2017.02.003","volume":"468","author":"LJ Zhang","year":"2017","unstructured":"Zhang, L. J. et al. Analysis of serum interleukin-27 and interleukin-35 concentrations in patients with Guillain-Barr\u00e9 syndrome. Clin Chim Acta 468, 5\u20139, https:\/\/doi.org\/10.1016\/j.cca.2017.02.003 (2017).","journal-title":"Clin Chim Acta"},{"key":"21025_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1750-3639.2002.tb00459.x","volume":"12","author":"L Bao","year":"2002","unstructured":"Bao, L. et al. The critical role of IL-12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental autoimmune neuritis. Brain Pathol 12, 420\u2013429 (2002).","journal-title":"Brain Pathol"},{"key":"21025_CR22","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nature01355","volume":"421","author":"DJ Cua","year":"2003","unstructured":"Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744\u2013748, https:\/\/doi.org\/10.1038\/nature01355 (2003).","journal-title":"Nature"},{"key":"21025_CR23","doi-asserted-by":"publisher","unstructured":"Lee, P. W. et al. IL-23R-activated STAT3\/STAT4 is essential for Th1\/Th17-mediated CNS autoimmunity. JCI Insight 2, https:\/\/doi.org\/10.1172\/jci.insight.91663 (2017).","DOI":"10.1172\/jci.insight.91663"},{"key":"21025_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.pnpbp.2017.07.023","volume":"79","author":"F Tahmasebinia","year":"2017","unstructured":"Tahmasebinia, F. & Pourgholaminejad, A. The role of Th17 cells in auto-inflammatory neurological disorders. Prog Neuropsychopharmacol Biol Psychiatry 79, 408\u2013416, https:\/\/doi.org\/10.1016\/j.pnpbp.2017.07.023 (2017).","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"21025_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/jnr.23233","volume":"91","author":"X Wang","year":"2013","unstructured":"Wang, X., Ma, C., Wu, J. & Zhu, J. Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barr\u00e9 syndrome as well as their animal models. J Neurosci Res 91, 871\u2013881, https:\/\/doi.org\/10.1002\/jnr.23233 (2013).","journal-title":"J Neurosci Res"},{"key":"21025_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/sji.12201","volume":"80","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. Mitigated Tregs and augmented Th17 cells and cytokines are associated with severity of experimental autoimmune neuritis. Scand J Immunol 80, 180\u2013190, https:\/\/doi.org\/10.1111\/sji.12201 (2014).","journal-title":"Scand J Immunol"},{"key":"21025_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","volume":"24","author":"M Veldhoen","year":"2006","unstructured":"Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M. & Stockinger, B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179\u2013189, https:\/\/doi.org\/10.1016\/j.immuni.2006.01.001 (2006).","journal-title":"Immunity"},{"key":"21025_CR28","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1074\/jbc.M207577200","volume":"278","author":"S Aggarwal","year":"2003","unstructured":"Aggarwal, S., Ghilardi, N., Xie, M. H., de Sauvage, F. J. & Gurney, A. L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278, 1910\u20131914, https:\/\/doi.org\/10.1074\/jbc.M207577200 (2003).","journal-title":"J Biol Chem"},{"key":"21025_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish, C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201, 233\u2013240, https:\/\/doi.org\/10.1084\/jem.20041257 (2005).","journal-title":"J Exp Med"},{"key":"21025_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1352458510384496","volume":"17","author":"TL Vollmer","year":"2011","unstructured":"Vollmer, T. L., Wynn, D. R., Alam, M. S. & Valdes, J. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler 17, 181\u2013191, https:\/\/doi.org\/10.1177\/1352458510384496 (2011).","journal-title":"Mult Scler"},{"key":"21025_CR31","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/00207454.2016.1231186","volume":"127","author":"NK Kharwar","year":"2017","unstructured":"Kharwar, N. K., Prasad, K. N., Singh, K., Paliwal, V. K. & Modi, D. R. Polymorphisms of IL-17 and ICAM-1 and their expression in Guillain-Barr\u00e9 syndrome. Int J Neurosci 127, 680\u2013687, https:\/\/doi.org\/10.1080\/00207454.2016.1231186 (2017).","journal-title":"Int J Neurosci"},{"key":"21025_CR32","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1096\/fj.201601147R","volume":"31","author":"H Liu","year":"2017","unstructured":"Liu, H. et al. PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th17-cell differentiation and regulating cytokine production. FASEB J 31, 1756\u20131766, https:\/\/doi.org\/10.1096\/fj.201601147R (2017).","journal-title":"FASEB J"},{"key":"21025_CR33","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","volume":"10","author":"BR Wakerley","year":"2014","unstructured":"Wakerley, B. R., Uncini, A., Yuki, N., Group, G. B. S. C. & Group, G. B. S. C. Guillain-Barr\u00e9 and Miller Fisher syndromes\u2013new diagnostic classification. Nat Rev Neurol 10, 537\u2013544, https:\/\/doi.org\/10.1038\/nrneurol.2014.138 (2014).","journal-title":"Nat Rev Neurol"},{"key":"21025_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3329\/jhpn.v28i6.6602","volume":"28","author":"KO Poropatich","year":"2010","unstructured":"Poropatich, K. O., Walker, C. L. & Black, R. E. Quantifying the association between Campylobacter infection and Guillain-Barr\u00e9 syndrome: a systematic review. J Health Popul Nutr 28, 545\u2013552 (2010).","journal-title":"J Health Popul Nutr"},{"issue":"Pt 3","key":"21025_CR35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/brain\/118.3.597","volume":"118","author":"TW Ho","year":"1995","unstructured":"Ho, T. W. et al. Guillain-Barr\u00e9 syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118(Pt 3), 597\u2013605 (1995).","journal-title":"Brain"},{"key":"21025_CR36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1074-7613(02)00324-2","volume":"16","author":"S Pflanz","year":"2002","unstructured":"Pflanz, S. et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4\u2009+\u2009T cells. Immunity 16, 779\u2013790 (2002).","journal-title":"Immunity"},{"key":"21025_CR37","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.4049\/jimmunol.179.10.6421","volume":"179","author":"S Wang","year":"2007","unstructured":"Wang, S., Miyazaki, Y., Shinozaki, Y. & Yoshida, H. Augmentation of antigen-presenting and Th1-promoting functions of dendritic cells by WSX-1(IL-27R) deficiency. J Immunol 179, 6421\u20136428 (2007).","journal-title":"J Immunol"},{"key":"21025_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4049\/jimmunol.176.1.237","volume":"176","author":"AV Villarino","year":"2006","unstructured":"Villarino, A. V. et al. IL-27 limits IL-2 production during Th1 differentiation. J Immunol 176, 237\u2013247 (2006).","journal-title":"J Immunol"},{"key":"21025_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1600-065X.2008.00710.x","volume":"226","author":"H Yoshida","year":"2008","unstructured":"Yoshida, H. & Miyazaki, Y. Regulation of immune responses by interleukin-27. Immunol Rev 226, 234\u2013247, https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00710.x (2008).","journal-title":"Immunol Rev"},{"key":"21025_CR40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jns.2014.11.035","volume":"348","author":"SC Tang","year":"2015","unstructured":"Tang, S. C., Fan, X. H., Pan, Q. M., Sun, Q. S. & Liu, Y. Decreased expression of IL-27 and its correlation with Th1 and Th17 cells in progressive multiple sclerosis. J Neurol Sci 348, 174\u2013180, https:\/\/doi.org\/10.1016\/j.jns.2014.11.035 (2015).","journal-title":"J Neurol Sci"},{"key":"21025_CR41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jneuroim.2015.09.010","volume":"288","author":"HN Jeong","year":"2015","unstructured":"Jeong, H. N., Lee, J. H., Suh, B. C. & Choi, Y. C. Serum interleukin-27 expression in patients with myasthenia gravis. J Neuroimmunol 288, 120\u2013122, https:\/\/doi.org\/10.1016\/j.jneuroim.2015.09.010 (2015).","journal-title":"J Neuroimmunol"},{"key":"21025_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jaut.2013.08.003","volume":"50","author":"WP Chong","year":"2014","unstructured":"Chong, W. P. et al. IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun 50, 12\u201322, https:\/\/doi.org\/10.1016\/j.jaut.2013.08.003 (2014).","journal-title":"J Autoimmun"},{"key":"21025_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/15321819.2016.1195746","volume":"37","author":"S Naderi","year":"2016","unstructured":"Naderi, S. et al. IL-27 plasma level in relapsing remitting multiple sclerosis subjects: The double-faced cytokine. J Immunoassay Immunochem 37, 659\u2013670, https:\/\/doi.org\/10.1080\/15321819.2016.1195746 (2016).","journal-title":"J Immunoassay Immunochem"},{"key":"21025_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2016.07.029","volume":"369","author":"H Liu","year":"2016","unstructured":"Liu, H. et al. Polymorphisms in exon 2 of CD1 genes are associated with susceptibility to Guillain-Barr\u00e9 syndrome. J Neurol Sci 369, 39\u201342, https:\/\/doi.org\/10.1016\/j.jns.2016.07.029 (2016).","journal-title":"J Neurol Sci"},{"key":"21025_CR45","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","volume":"6","author":"R van Koningsveld","year":"2007","unstructured":"van Koningsveld, R. et al. A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome. Lancet Neurol 6, 589\u2013594, https:\/\/doi.org\/10.1016\/S1474-4422(07)70130-8 (2007).","journal-title":"Lancet Neurol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21025-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21025-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21025-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:16:31Z","timestamp":1671588991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21025-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["21025"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-21025-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,12]]},"assertion":[{"value":"7 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2824"}}